B
ERLIN--GPC, a genomics-based drug discovery company headquartered in Munich, and Atugen, a target discovery and validation company here, announced a strategic alliance to provide life sciences companies with an integrated functional genomics and proteomics platform to identify and validate novel drug discovery targets. The combined technology platforms can be applied to major diseases such as cancer and metabolic disorders as well as central nervous system and heart ailments.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.